|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2006-5-18
|
|
pubmed:abstractText |
Significant variability in the efficacy and toxicity of an anticancer drug is observed in cancer patients. Currently, there are no standard tools for prediction of a patient's tumor response or his risk of adverse events to chemotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1744-6872
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
429-38
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16708051-Antimetabolites, Antineoplastic,
pubmed-meshheading:16708051-Brain Neoplasms,
pubmed-meshheading:16708051-Breast Neoplasms,
pubmed-meshheading:16708051-Cell Line, Tumor,
pubmed-meshheading:16708051-Colorectal Neoplasms,
pubmed-meshheading:16708051-DCMP Deaminase,
pubmed-meshheading:16708051-Deoxycytidine,
pubmed-meshheading:16708051-Deoxycytidine Kinase,
pubmed-meshheading:16708051-Drug Resistance, Neoplasm,
pubmed-meshheading:16708051-Female,
pubmed-meshheading:16708051-Humans,
pubmed-meshheading:16708051-Inhibitory Concentration 50,
pubmed-meshheading:16708051-Lung Neoplasms,
pubmed-meshheading:16708051-Polymorphism, Genetic,
pubmed-meshheading:16708051-Polymorphism, Single Nucleotide,
pubmed-meshheading:16708051-Stomach Neoplasms,
pubmed-meshheading:16708051-Tumor Suppressor Proteins
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.
|
|
pubmed:affiliation |
Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, Seodaemun-Gu, Seoul, Korea.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
In Vitro,
Research Support, Non-U.S. Gov't
|
